Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.
Renfro, Lindsay A. , Seymour, Michel , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Porschen, Rainer, Tournigand, Christophe , Hecht, J. Randolph, Punt, Cornelis J.A. , Goldberg, Richard M. , Gramont, Aimery de , Lenz, Heinz‐Josef , Seymour, Matthew T , Loupakis, Fotios , Adams, Richard , Schmoll, Hans‐Joachim , Díaz‐Rubio, Eduardo , Falcone, Alfredo , Tebbutt, Niall C. , Saltz, Leonard B. , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3537-3537

10.1200/jco.2014.32.15_suppl.3537 Get It

Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-
Somlo, George, Frankel, Paul , Luu, Thehang, Cynthia, X. , García, Agustin A. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Nanda, Rita , Chew, Helen K. , Moynihan, Timothy J. , Hurria, Arti , Chen, Alice P. , Arun, Banu , Sparano, Joseph A. , Vahdat, Linda T. , Goetz, Matthew P. , Mortimer, Joanne , Gandara, David R. , Weitzel, Jeffrey N.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 1021-1021

10.1200/jco.2014.32.15_suppl.1021 Get It

Outcome Characteristics of Multiple-Valve Surgery
Vassileva, Christina M., Li, Shuang , Thourani, Vinod H. , Suri, Rakesh M. , Lee, Richard, Rankin, J. Scott , Williams, Matthew L.

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 9 | Issue: 1 | Pages: 27-32

10.1177/155698451400900105 Get It

Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.
Ferraro, Danielle , Meyers, Jeffrey P., Seymour, Michel , Goldberg, Richard M. , Heinemann, Volker , Hurwitz, Herbert I. , Chibaudel, Benoist , Fuchs, Charles S. , Porschen, Rainer, Bokemeyer, Carsten , Gramont, Aimery de , Seymour, Matthew T , Zalcberg, John , Shi, Qian , Saltz, Leonard B. , Maughan, Tim , Cutsem, Eric Van , Falcone, Alfredo , Díaz‐Rubio, Eduardo , Price, Timothy Jay , Adams, Richard , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 617-617

10.1200/jco.2018.36.4_suppl.617 Get It

617 Background: There is limited, often conflicting evidence about AE timing, severity or associations with outcomes with the use of cytotoxic agents in cancer treatment. We investigated the impact on overall survival (OS) and progression-free survival (PFS) of selected common AEs (neutropenia, diarrhea, nausea, vomiting, neuropathy) occurring in patients receiving first line oxaliplatin (Oxa)- and/or irinotecan(Iri)-based regimens for mCRC. Methods: The CTCAE grading scores of at least one AE of interest were available on 9812 pts treated with chemotherapy alone (median age 63; 62.4% male, 50.1% ECOG PS 0) from 17 1st-line randomized trials. Patients who also received biologics were excluded in the primary analyses. AEs occurring during the first 6 weeks of treatment and entire treatment were analyzed by stratified multivariable Cox models in relationship to OS/PFS. 55.7% pts received Oxa- regimens, 35.7% Iri-regimens, and 8.6% combined Oxa- and Iri-regimens. Results: Within the first 6 weeks of treatment, G3+ neutropenia (HRadj= 1.3, 95% CI, 1.06-1.59, padj 0.01), diarrhea (HRadj= 1.48, 95% CI, 1.23-1.79, padj < .0001), nausea (HRadj= 1.53, 95% CI, 1.17-1.99, padj 0.002) and vomiting (HRadj= 1.56, 95% CI, 1.18-2.07, padj 0.002) were associated with significantly worse OS for Iri-regimens, but only G3+ nausea predicted for worse OS for Oxa- regimens (HRadj= 1.61, 95% CI, 1.18-2.21, padj 0.003). For AEs experienced at any time, G3+ neutropenia and neuropathy were significantly associated with longer PFS and OS for Oxa-regimens, while G3+ vomiting and nausea were associated with worse OS for both Oxa- and Iri-based regimens. Sensitivity analysis showed largely concordant results by including pts who also received biologics. Conclusions: The association between more severe selected AEs and outcome varies between AEs and is influenced by timing of the occurrence. More severe selected AEs occurring early in treatment are associated with worse outcomes. In contrast, for AEs occurring at any time, G3+ neutropenia and neuropathy predicted for longer PFS and/or OS in Oxa-treated pts.
Long-term outcomes of liver transplantation (LT) for the treatment of neuroendocrine liver metastases (NELM): The Mayo Clinic experience.
Ahn, Daniel H. , Mathur, Amit K. , DeLeon, Thomas, Hálfdánarson, Þorvarður R. , Hobday, Timothy J. , Ramanathan, Ramesh K., Mody, Kabir , Stucky, Chee‐Chee , Truty, Mark J. , Moss, Adyr A. , Halfdanarson, Thorvardur R , Sonbol, Mohamad Bassam , Buras, Matthew , Borad, Mitesh J. , Gores, Gregory J. , Heimbach, Julie K. , Taner, C. Burcin , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 355-355

10.1200/jco.2018.36.4_suppl.355 Get It

355 Background: In this study, we sought to determine the prognostic factors impacting survival of patients with NELM who underwent LT at Mayo Clinic. Methods: We performed a three-site retrospective analysis of patients with unresectable NELM treated with LT from 1990 -2017. Cases were identified from clinical databases at Mayo Clinic. Data on demographics, timing of diagnosis and transplant, extent of liver involvement, and tumor grade, were extracted. Extent of liver involvement was calculated using previously validated standardized volumetry with high defined as > 25% increase in the weight of the extracted liver at the time of the transplant as compared to the standard liver volume. Survival was calculated using the Kaplan–Meier method. Results: We identified 37 patients. Median age at LT was 47 (range 17.0-64.0), male: female (73% vs. 27%, respectively). Primary tumor site was in the pancreas in 51.3% and in the small bowels in 43.2%; 78.4% had NELM at presentation. While primary tumor resection was done at the time of LT in 5 (13.9%) cases, most patients (80.6%) had ˃6-months interval between primary tumor resection and LT surgery. Prior to LT, 25 (74.3%) patients received somatostatin analogues and 18 (61.3%) had liver-directed therapy. Median time from diagnosis to transplant was 33.6 months (0-246). High extent of liver involvement was identified in 12 patients (33.3%). Disease-Free Survival (DFS) at 3, 5, and 10 years was 56.8%, 43.1%, and 22.4% respectively. Overall-survival (OS) at 3, 5, and 10 years was 86.9%, 79.6%, and 52.6% respectively. High extent of liver involvement at the time of transplantation was associated with inferior DFS and OS and patients˃45 years-old at the time of transplantation had worse DFS. Patients whose disease met the OPTN (Organ Procurement and Transplantation Network) criteria for NELM transplantation had significantly better DFS and OS with median 10-year OS of 80.7 % vs. 17%. Conclusions: LT is a reasonable therapeutic option for selected patients with unresectable NELM with 10-year OS of 52.6%. High extent of liver involvement was associated with worse long-term outcomes while meeting OPTN criteria resulted in best outcomes.
Implications of pancreatic cancer with diabetes mellitus on patient outcomes and care: A matched case-control study.
Karlin, Nina J. , Amin, Shailja B , Verona, Patricia M , Buras, Matthew , Kosiorek, Heidi , Cook, Curtiss B.

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 239-239

10.1200/jco.2018.36.4_suppl.239 Get It

239 Background: The aim of this case-control study was to determine the impact of DM on survival in pancreatic cancer patients, and to examine the impact of pancreatic cancer on glycemic control in DM. Methods: Ninety-two patients with newly diagnosed pancreatic cancer from 2007 to 2015 with DM were identified from the institutional Cancer Registry and matched to ninety-two pancreatic cancer patients without DM according to age, gender, and year of pancreatic cancer diagnosis. The file was linked to the electronic medical record to obtain information on DM and pancreatic cancer therapies, and laboratory results. Overall survival (OS) was estimated with the Kaplan-Meier method and compared by Cox regression analysis. Mixed models were used to compare hemoglobin A1c (HbA1c) and glucose over time. Results: Mean age of the entire pancreatic cancer cohort was 70 years, most (92%) were white, most common (88%) histology was adenocarcinoma, and majority (41%) were stage IV. No differences in age, race/ethnicity, histology, or tumor stage were detected between patients with and without DM, although DM patients had higher body mass index (P = 0.014). Mean ca 19-9 (U/ml) was 804 for diabetics, and 395 for non-diabetics. Among those with DM the mean HbA1c during the year following cancer diagnosis was 7.3%. Time (days since diagnosis) was significant in DM patients (p = 0.014) as HbA1c decreased over time. Mean glucose during the year following diagnosis among DM patients was significantly higher compared to non-DM patients [160.6 (SD = 38.0) versus 117.2 (SD = 19.0); p < 0.001]. Both groups had a decline in glucose over time (p = 0.008). In Kaplan-Meier survival analysis (median follow-up time of 11.9 months), 2 year overall survival was estimated at 15% [95% CI: 8-24%] for DM patients versus 26% [95% CI: 17-36%] in non-DM patients. Hazard ratio (for matched pairs) was 1.15 (95% CI: 0.75-1.77; p = 0.51). Conclusions: DM did not adversely impact survival in patients with pancreatic cancer. Pancreatic cancer did not affect glycemic control. Elevated ca 19-9 in diabetic patients may be an unreliable marker for gauging disease progression.
IP 112. Cannabidiol Treatment Effect and Adverse Events in Patients with Lennox–Gastaut’s syndrome: Pooled Results from Two Trials
Privitera, Michael , Bhathal, Hari, Sommerville, Kenneth W. , Roberts, Claire , Cross, J. Helen , Cross, Helen J , Gil‐Nagel, António , Wong, Matthew, Cross, J., Wirrell, Elaine

Mayo Clinic

Neuropediatrics | January 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1676030 Get It

Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer
Moschini, Marco , Sharma, Vidit , Soligo, Matteo, Rangel, Laureano J. , Boorjian, Stephen A. , Frank, Igor, Gettman, Matthew T., Thompson, R. Houston, Tollefson, Matthew K. , Karnes, R. Jeffrey , Psutka, Sarah, Rangel, Laureano, Moschini, Marco , Psutka, Sarah P.

Mayo Clinic

Scandinavian Journal of Urology | January 2, 2019 | Volume: 52 | Issue: 5-6 | Pages: 340-348

10.1080/21681805.2018.1534886 | PMID 30600747 Get It

Coffee Talk: A Jolt for Night Shift Education
Margretta, Margaret, McLaughlin, Diane , Dennis, Matthew, McLaughlin, Diane C, Dennis, Matthew

Mayo Clinic

American Journal of Critical Care | January 1, 2019 | Volume: 28 | Issue: 1 | Pages: 81-84

10.4037/ajcc2019709 | PMID 30600231 Get It

Background Education opportunities for night shift nurses are limited compared with those for their day-shift counterparts. However, patients remain critically ill regardless of shift and require intensive nursing care at all hours. Overnight, this care is often provided with fewer resources. These challenges can lead to disengagement and high turnover on the night shift. Objectives To see whether initiation of an informal education series called “Coffee Talk” could improve accessibility to learning for night shift nurses and elevate perception of support from administrators and overall job satisfaction. Methods The lecture series was created to facilitate education for night shift nurses. The program features various speakers within the interdisciplinary team discussing topics chosen by the nursing staff. The talks are presented in an informal setting during overnight hours. An electronic survey tool was used to determine nurses’ opinions regarding Coffee Talk, using a retrospective pretest and posttest format. Questions centered on the type of educational offerings, relevance to practice, perceived leadership support, convenience of attendance, and overall job satisfaction. Results More than half of the nurses (59%) responded. All scores improved from before to after the intervention. The largest increases occurred in convenience of educational offerings and nurses’ perception of leaders removing barriers to learning. Overall job satisfaction increased from 83% to 93%. Conclusions The introduction of an informal educational series improved nurses’ access to education and nurses’ feelings of support from administrators and overall job satisfaction.
Factors at de novo donor‐specific antibody initial detection associated with allograft loss: a multicenter study
Schinstock, Carrie A. , Dadhania, Darshana M. , Everly, Matthew J. , Smith, Byron H. , Gandhi, Manish J. , Farkash, Evan A. , Samaniego, Milagros , Stegall, Mark D. , Smith, Byron , Gandhi, Manish, Stegall, Mark D , Schinstock, Carrie , Sharma, Vijay Kumar , Samaniego-Picota, Milagros

Mayo Clinic

Transplant International | December 31, 2018 | Volume: 32 | Issue: 5 | Pages: 502-515

10.1111/tri.13395 | PMID 30597643 Get It